QcrB inhibition as a potential approach for the treatment of tuberculosis: A review of recent developments, patents, and future directions

Mohd Imran; Abida; Nawaf M Alotaibi; Hamdy K Thabet; Jamal A Alruwaili; Syed M B Asdaq; Lina Eltaib; Ahmed Alshehri; Ahad A Alsaiari; Mazen Almehmadi; Amal B Hommod Alshammari; Abdulmajeed M Alshammari

doi:10.1016/j.jiph.2023.04.011

QcrB inhibition as a potential approach for the treatment of tuberculosis: A review of recent developments, patents, and future directions

J Infect Public Health. 2023 Jun;16(6):928-937. doi: 10.1016/j.jiph.2023.04.011. Epub 2023 Apr 13.

Authors

Affiliations

¹ Department of Pharmaceutical Chemistry, College of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia. Electronic address: mohammad.baks@nbu.edu.sa.
² Department of Pharmaceutical Chemistry, College of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
³ Department of Clinical Pharmacy, College of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia; Chemistry Department, College of Sciences and Arts, Northern Border University, Rafha 91911, Saudi Arabia.
⁴ Chemistry Department, College of Sciences and Arts, Northern Border University, Rafha 91911, Saudi Arabia.
⁵ College of Applied Medical Sciences, Medical Lab Technology Department, Northern Border University, Arar 91431, Saudi Arabia.
⁶ Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.
⁷ Department of Pharmaceutics, College of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
⁸ Department of Pharmacology and Toxicology, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia; Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, King Faisal Road, Dammam 31441, Saudi Arabia.
⁹ Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
¹⁰ College of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.

PMID: 37086552
DOI: 10.1016/j.jiph.2023.04.011

Abstract

The unmet medical need for drug-resistant tuberculosis (DRTB) is a significant concern. Accordingly, identifying new drug targets for tuberculosis (TB) treatment and developing new therapies based on these drug targets is one of the strategies to tackle DRTB. QcrB is an innovative drug target to create treatments for DRTB. This article highlights QcrB inhibitors and their therapeutic compositions for treating TB. The literature for this article was gathered from PubMed and free patent databases utilizing different keywords related to QcrB inhibitor-based inventions. The data was collected from the conceptualization of telacebec (2010) QcrB to December 2022. A little interesting and encouraging research has been performed on QcrB inhibitors. Telacebec and TB47 are established QcrB inhibitors in the clinical trial. The inventive QcrB inhibitor-based drug combinations can potentially handle DRTB and reduce the TB therapy duration. The authors anticipate great opportunities in fostering QcrB inhibitor-based patentable pharmaceutical inventions against TB. Drug repurposing can be a promising strategy to get safe and effective QcrB inhibitors. However, developing drug resistance, drug tolerance, and selectivity of QcrB inhibitors for Mtb will be the main challenges in developing effective QcrB inhibitors. In conclusion, QcrB is a promising drug target for developing effective treatments for active, latent, and drug-resistant TB. Many inventive and patentable combinations and compositions of QcrB inhibitors with other anti-TB drugs are anticipated as future treatments for TB.

Keywords: Patent; QcrB inhibitors; Telacebec; Treatment; Tuberculosis.

Publication types

Review

MeSH terms

Antitubercular Agents / pharmacology
Antitubercular Agents / therapeutic use
Humans
Mycobacterium tuberculosis*
Tuberculosis* / drug therapy
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Antitubercular Agents